Please login to the form below

Not currently logged in
Email:
Password:

EPO

This page shows the latest EPO news and features for those working in and with pharma, biotech and healthcare.

Pfizer gets FDA panel recommendation for biosimilar EPO

Pfizer gets FDA panel recommendation for biosimilar EPO

Pfizer gets FDA panel recommendation for biosimilar EPO. Product could be the first direct competitor to Epogen and Procrit in the US.

Latest news

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    product. (According to the journal Biosimilar Development the price of EPO in Norway was sold at an 83% discount from the original price.).

  • Can biosimilars live up to the hype? Can biosimilars live up to the hype?

    For instance, in Germany, an estimated 0.5bn has been saved with the introduction of Epo biosimilars and there has been a dramatic expansion in the use of the biosimilar filgrastim

  • Deal Watch February 2016 Deal Watch February 2016

    licence. 105. †† Genexine/ Shanghai Chemo WanBang Biopharma. GX-E2 (EPO-hyFc), a novel Fc-engineered (hyFc) long acting EPO, for anaemia due to chronic kidney disease and chemotherapy.

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    EPO-Fc. EPO-hybrid Fc. Anaemia. S Korea. Phase I. Hanferon (HL143). HanAll Biopharma. ... Hormone deficiency. S Korea. Phase I Completed Dec 2011. HL033. Improved EPO.

  • Country report: The healthcare market in Germany Country report: The healthcare market in Germany

    For instance, the launch of EPO has contributed to considerable public savings.OTC drugs are sold in pharmacies only (some herbal medicines and supplements can be sold in other stores) and

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics